Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4-week dose-finding oral Eubacterium hallii trial in men with metabolic syndrome
NL-OMON22563Active, not recruiting
- Sponsor
- AMC Health
- Start
- Nov 2014
- Countries
- 1
01
Overview
Open-label, single-arm trial in cardiometabolic risk (CMR), metabolic dysfunction-associated steatotic liver disease (MASLD), insulin resistance (IR) and 1 more, sponsored by AMC Health. Primary endpoints: Safety and fecal Eubacterium hallii increase and Insulin sensitivity. Started Nov 2014; status: active, not recruiting.
02
Conditions
cardiometabolic risk (CMR)metabolic dysfunction-associated steatotic liver disease (MASLD)insulin resistance (IR)obesity
Beyond the preview
Go deeper on NL-OMON22563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22563.